APO Research
Talk to an analyst

APO RESEARCH · REPORT

Community-acquired Bacterial Pneumonia

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Community-acquired Bacterial Pneumonia Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchCommunity-acquired Bacterial Pneumonia Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Community-acquired Bacterial Pneumonia Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Community-acquired Bacterial Pneumonia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Community-acquired Bacterial Pneumonia Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Community-acquired Bacterial Pneumonia Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Community-acquired Bacterial Pneumonia market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Community-acquired Bacterial Pneumonia market include Takeda Pharmaceutical Company Limited, Sanofi S.A., Mylan N.V., Pfizer Inc., Bayer AG, Paratek Pharmaceuticals, Nabriva Therapeutics, Melinta Therapeutics and Lupin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Community-acquired Bacterial Pneumonia market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Community-acquired Bacterial Pneumonia and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Community-acquired Bacterial Pneumonia revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Community-acquired Bacterial Pneumonia market.

Community-acquired Bacterial Pneumonia Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Mylan N.V.

Pfizer Inc.

Bayer AG

Paratek Pharmaceuticals

Nabriva Therapeutics

Melinta Therapeutics

Lupin Pharmaceuticals

Dainippon Sumitomo Pharma

Basilea Pharmaceutica International AG

Allergan plc

Community-acquired Bacterial Pneumonia Segment by Type

Oxazolidinone

Glycylcycline

Pleuromutilin Antibiotic

Ketolide

Cephalosporin

Others

Community-acquired Bacterial Pneumonia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Community-acquired Bacterial Pneumonia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Community-acquired Bacterial Pneumonia status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Community-acquired Bacterial Pneumonia key companies, revenue, market share, and recent developments.

3. To split the Community-acquired Bacterial Pneumonia breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Community-acquired Bacterial Pneumonia market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Community-acquired Bacterial Pneumonia significant trends, drivers, influence factors in global and regions.

6. To analyze Community-acquired Bacterial Pneumonia competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community-acquired Bacterial Pneumonia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Community-acquired Bacterial Pneumonia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community-acquired Bacterial Pneumonia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Community-acquired Bacterial Pneumonia industry.

Chapter 3: Detailed analysis of Community-acquired Bacterial Pneumonia company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Community-acquired Bacterial Pneumonia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Community-acquired Bacterial Pneumonia in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Community-acquired Bacterial Pneumonia Industry Trends Table 2. Community-acquired Bacterial Pneumonia Industry Drivers Table 3. Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges Table 4. Community-acquired Bacterial Pneumonia Industry Restraints Table 5. Global Community-acquired Bacterial Pneumonia Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Community-acquired Bacterial Pneumonia Revenue Share by Company (2021-2026) Table 7. Global Community-acquired Bacterial Pneumonia Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Community-acquired Bacterial Pneumonia Key Company Manufacturing Base & Headquarters Table 9. Global Community-acquired Bacterial Pneumonia Company, Product Type & Application Table 10. Global Community-acquired Bacterial Pneumonia Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oxazolidinone Table 15. Significant Companies of Glycylcycline Table 16. Significant Companies of Pleuromutilin Antibiotic Table 17. Significant Companies of Ketolide Table 18. Significant Companies of Cephalosporin Table 19. Significant Companies of Others Table 20. Global Community-acquired Bacterial Pneumonia Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Community-acquired Bacterial Pneumonia Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Community-acquired Bacterial Pneumonia Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Community-acquired Bacterial Pneumonia Sales Value Share by Type (2021-2026) Table 24. Global Community-acquired Bacterial Pneumonia Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Retail Pharmacies Table 26. Significant Companies of Online Pharmacies Table 27. Significant Companies of Hospital Pharmacies Table 28. Global Community-acquired Bacterial Pneumonia Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Community-acquired Bacterial Pneumonia Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Community-acquired Bacterial Pneumonia Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Community-acquired Bacterial Pneumonia Sales Value Share by Application (2021-2026) Table 32. Global Community-acquired Bacterial Pneumonia Sales Value Share by Application (2027-2032) Table 33. Global Community-acquired Bacterial Pneumonia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Community-acquired Bacterial Pneumonia Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Community-acquired Bacterial Pneumonia Sales Value Share by Region (2021-2026) Table 36. Global Community-acquired Bacterial Pneumonia Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Community-acquired Bacterial Pneumonia Sales Value Share by Region (2027-2032) Table 38. Global Community-acquired Bacterial Pneumonia Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Community-acquired Bacterial Pneumonia Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Community-acquired Bacterial Pneumonia Sales Value Market Share by Country (2021-2026) Table 41. Global Community-acquired Bacterial Pneumonia Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Community-acquired Bacterial Pneumonia Sales Value Market Share by Country (2027-2032) Table 43. Takeda Pharmaceutical Company Limited Company Information Table 44. Takeda Pharmaceutical Company Limited Business Overview Table 45. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio Table 47. Takeda Pharmaceutical Company Limited Recent Development Table 48. Sanofi S.A. Company Information Table 49. Sanofi S.A. Business Overview Table 50. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio Table 52. Sanofi S.A. Recent Development Table 53. Mylan N.V. Company Information Table 54. Mylan N.V. Business Overview Table 55. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio Table 57. Mylan N.V. Recent Development Table 58. Pfizer Inc. Company Information Table 59. Pfizer Inc. Business Overview Table 60. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio Table 62. Pfizer Inc. Recent Development Table 63. Bayer AG Company Information Table 64. Bayer AG Business Overview Table 65. Bayer AG Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio Table 67. Bayer AG Recent Development Table 68. Paratek Pharmaceuticals Company Information Table 69. Paratek Pharmaceuticals Business Overview Table 70. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 72. Paratek Pharmaceuticals Recent Development Table 73. Nabriva Therapeutics Company Information Table 74. Nabriva Therapeutics Business Overview Table 75. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 77. Nabriva Therapeutics Recent Development Table 78. Melinta Therapeutics Company Information Table 79. Melinta Therapeutics Business Overview Table 80. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 82. Melinta Therapeutics Recent Development Table 83. Lupin Pharmaceuticals Company Information Table 84. Lupin Pharmaceuticals Business Overview Table 85. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 87. Lupin Pharmaceuticals Recent Development Table 88. Dainippon Sumitomo Pharma Company Information Table 89. Dainippon Sumitomo Pharma Business Overview Table 90. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio Table 92. Dainippon Sumitomo Pharma Recent Development Table 93. Basilea Pharmaceutica International AG Company Information Table 94. Basilea Pharmaceutica International AG Business Overview Table 95. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio Table 97. Basilea Pharmaceutica International AG Recent Development Table 98. Allergan plc Company Information Table 99. Allergan plc Business Overview Table 100. Allergan plc Community-acquired Bacterial Pneumonia Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio Table 102. Allergan plc Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Community-acquired Bacterial Pneumonia Product Image Figure 2. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 4. Global Community-acquired Bacterial Pneumonia Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oxazolidinone Image Figure 8. Glycylcycline Image Figure 9. Pleuromutilin Antibiotic Image Figure 10. Ketolide Image Figure 11. Cephalosporin Image Figure 12. Others Image Figure 13. Global Community-acquired Bacterial Pneumonia Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Community-acquired Bacterial Pneumonia Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Community-acquired Bacterial Pneumonia Sales Value Share by Type (2021-2032) Figure 16. Retail Pharmacies Image Figure 17. Online Pharmacies Image Figure 18. Hospital Pharmacies Image Figure 19. Global Community-acquired Bacterial Pneumonia Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Community-acquired Bacterial Pneumonia Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Community-acquired Bacterial Pneumonia Sales Value Share by Application (2021-2032) Figure 22. Global Community-acquired Bacterial Pneumonia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Community-acquired Bacterial Pneumonia Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Community-acquired Bacterial Pneumonia Sales Value (2021-2032) & (US$ Million) Figure 25. North America Community-acquired Bacterial Pneumonia Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Community-acquired Bacterial Pneumonia Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Community-acquired Bacterial Pneumonia Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Community-acquired Bacterial Pneumonia Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Community-acquired Bacterial Pneumonia Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Community-acquired Bacterial Pneumonia Sales Value (2021-2032) & (US$ Million) Figure 31. South America Community-acquired Bacterial Pneumonia Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Community-acquired Bacterial Pneumonia Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Community-acquired Bacterial Pneumonia Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Oxazolidinone
  • Glycylcycline
  • Pleuromutilin Antibiotic
  • Ketolide
  • Cephalosporin
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Lupin Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Basilea Pharmaceutica International AG
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Community-acquired Bacterial Pneumonia Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Community-acquired Bacterial Pneumonia Market Dynamics
  1. 2.1 Community-acquired Bacterial Pneumonia Industry Trends
  2. 2.2 Community-acquired Bacterial Pneumonia Industry Drivers
  3. 2.3 Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges
  4. 2.4 Community-acquired Bacterial Pneumonia Industry Restraints
3 Community-acquired Bacterial Pneumonia Market by Company
  1. 3.1 Global Community-acquired Bacterial Pneumonia Company Revenue Ranking in 2025
  2. 3.2 Global Community-acquired Bacterial Pneumonia Revenue by Company (2021-2026)
  3. 3.3 Global Community-acquired Bacterial Pneumonia Company Ranking (2024-2026)
  4. 3.4 Global Community-acquired Bacterial Pneumonia Company Manufacturing Base and Headquarters
  5. 3.5 Global Community-acquired Bacterial Pneumonia Company Product Type and Application
  6. 3.6 Global Community-acquired Bacterial Pneumonia Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Community-acquired Bacterial Pneumonia Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Community-acquired Bacterial Pneumonia Market by Type
  1. 4.1 Community-acquired Bacterial Pneumonia Type Introduction
  2. 4.1.1 Oxazolidinone
  3. 4.1.2 Glycylcycline
  4. 4.1.3 Pleuromutilin Antibiotic
  5. 4.1.4 Ketolide
  6. 4.1.5 Cephalosporin
  7. 4.1.6 Others
  8. 4.2 Global Community-acquired Bacterial Pneumonia Sales Value by Type
  9. 4.2.1 Global Community-acquired Bacterial Pneumonia Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Community-acquired Bacterial Pneumonia Sales Value by Type (2021-2032)
  11. 4.2.3 Global Community-acquired Bacterial Pneumonia Sales Value Share by Type (2021-2032)
5 Community-acquired Bacterial Pneumonia Market by Application
  1. 5.1 Community-acquired Bacterial Pneumonia Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Community-acquired Bacterial Pneumonia Sales Value by Application
  6. 5.2.1 Global Community-acquired Bacterial Pneumonia Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Community-acquired Bacterial Pneumonia Sales Value by Application (2021-2032)
  8. 5.2.3 Global Community-acquired Bacterial Pneumonia Sales Value Share by Application (2021-2032)
6 Community-acquired Bacterial Pneumonia Regional Value Analysis
  1. 6.1 Global Community-acquired Bacterial Pneumonia Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Community-acquired Bacterial Pneumonia Sales Value by Region (2021-2032)
  3. 6.2.1 Global Community-acquired Bacterial Pneumonia Sales Value by Region: 2021-2026
  4. 6.2.2 Global Community-acquired Bacterial Pneumonia Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Community-acquired Bacterial Pneumonia Sales Value (2021-2032)
  7. 6.3.2 North America Community-acquired Bacterial Pneumonia Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Community-acquired Bacterial Pneumonia Sales Value (2021-2032)
  10. 6.4.2 Europe Community-acquired Bacterial Pneumonia Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Community-acquired Bacterial Pneumonia Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Community-acquired Bacterial Pneumonia Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Community-acquired Bacterial Pneumonia Sales Value (2021-2032)
  16. 6.6.2 South America Community-acquired Bacterial Pneumonia Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Community-acquired Bacterial Pneumonia Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Community-acquired Bacterial Pneumonia Sales Value Share by Country, 2025 VS 2032
7 Community-acquired Bacterial Pneumonia Country-level Value Analysis
  1. 7.1 Global Community-acquired Bacterial Pneumonia Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Community-acquired Bacterial Pneumonia Sales Value by Country (2021-2032)
  3. 7.2.1 Global Community-acquired Bacterial Pneumonia Sales Value by Country (2021-2026)
  4. 7.2.2 Global Community-acquired Bacterial Pneumonia Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Community-acquired Bacterial Pneumonia Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Community-acquired Bacterial Pneumonia Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Community-acquired Bacterial Pneumonia Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Sanofi S.A.
  8. 8.2.1 Sanofi S.A. Company Information
  9. 8.2.2 Sanofi S.A. Business Overview
  10. 8.2.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio
  12. 8.2.5 Sanofi S.A. Recent Developments
  13. 8.3 Mylan N.V.
  14. 8.3.1 Mylan N.V. Company Information
  15. 8.3.2 Mylan N.V. Business Overview
  16. 8.3.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio
  18. 8.3.5 Mylan N.V. Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Bayer AG
  26. 8.5.1 Bayer AG Company Information
  27. 8.5.2 Bayer AG Business Overview
  28. 8.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio
  30. 8.5.5 Bayer AG Recent Developments
  31. 8.6 Paratek Pharmaceuticals
  32. 8.6.1 Paratek Pharmaceuticals Company Information
  33. 8.6.2 Paratek Pharmaceuticals Business Overview
  34. 8.6.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  36. 8.6.5 Paratek Pharmaceuticals Recent Developments
  37. 8.7 Nabriva Therapeutics
  38. 8.7.1 Nabriva Therapeutics Company Information
  39. 8.7.2 Nabriva Therapeutics Business Overview
  40. 8.7.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  42. 8.7.5 Nabriva Therapeutics Recent Developments
  43. 8.8 Melinta Therapeutics
  44. 8.8.1 Melinta Therapeutics Company Information
  45. 8.8.2 Melinta Therapeutics Business Overview
  46. 8.8.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  48. 8.8.5 Melinta Therapeutics Recent Developments
  49. 8.9 Lupin Pharmaceuticals
  50. 8.9.1 Lupin Pharmaceuticals Company Information
  51. 8.9.2 Lupin Pharmaceuticals Business Overview
  52. 8.9.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  54. 8.9.5 Lupin Pharmaceuticals Recent Developments
  55. 8.10 Dainippon Sumitomo Pharma
  56. 8.10.1 Dainippon Sumitomo Pharma Company Information
  57. 8.10.2 Dainippon Sumitomo Pharma Business Overview
  58. 8.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio
  60. 8.10.5 Dainippon Sumitomo Pharma Recent Developments
  61. 8.11 Basilea Pharmaceutica International AG
  62. 8.11.1 Basilea Pharmaceutica International AG Company Information
  63. 8.11.2 Basilea Pharmaceutica International AG Business Overview
  64. 8.11.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio
  66. 8.11.5 Basilea Pharmaceutica International AG Recent Developments
  67. 8.12 Allergan plc
  68. 8.12.1 Allergan plc Company Information
  69. 8.12.2 Allergan plc Business Overview
  70. 8.12.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio
  72. 8.12.5 Allergan plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst